NCT00073502已完成2 期
A Phase II Study of Single Agent OSI-7904L In Patients With Locally Advanced or Metastatic Adenocarcinoma Of the Stomach or Gastroesophageal Junction
OSI Pharmaceuticals21 个研究点 分布在 3 个国家目标入组 43 人开始时间: 2003年10月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 43
- 试验地点
- 21
研究概览
简要总结
Multi-center, open-label, non-randomized Phase II study to evaluate the efficacy and safety of OSI-7904L in gastric and GEJ cancers. Those patients who do not derive clinical benefit after two cycles may be switched to a commonly used combination regimen.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Documented locally advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction No prior chemotherapy for locally advanced or metastatic disease Adequate baseline bone marrow, hepatic and renal function Age >= 18 years At least one target lesion
排除标准
- •Active or uncontrolled infections or other serious illnesses or other medical conditions (eg, hepatitis, HIV, chronic alcohol abuse) Symptomatic brain metastases which are not stable
研究者
研究点 (21)
Loading locations...
相似试验
已完成
2 期
A Study of OSI-7904L as Treatment in Patients With Head and Neck Cancer Who Have Failed First-Line TherapyLocally Recurrent or Metastatic Cancer of the Head and NeckMust Have Failed First-Line TherapyNCT00116909OSI Pharmaceuticals85
已完成
2 期
A Study of OSI-7904L Versus 5-FU/LV as Treatment in Patients With Biliary Tract CancerLocally Advanced or Metastatic Adenoca of the Biliary TractNCT00088270OSI Pharmaceuticals58
已完成
2 期
A Study to Evaluate Erlotinib in Patients With Advanced or Metastatic Breast Cancer During or Following ChemotherapyBreast CancerNCT00109265Genentech, Inc.
终止
1 期
A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple MyelomaMultiple MyelomaNCT01672736University Health Network, Toronto19
已完成
2 期
Study of IMP4297 in Patients With BRCA1/2 Mutation Ovarian CancerOvarian CancerNCT04089189Impact Therapeutics, Inc.93